First off, Abbott is not sending back the test. Secondly, the offers so far by other MAJOR pharmaceutical companies must be in the same league as the Abbott deal or we are selling ourselves short, so there have been offers, but the # of licensees permitted by the "semi-exclusive "contract would be not be beneficial to do a deal at a lower royalty. I suggest you call management to answer your questions before you start any hypothetical conclusions and spread false rumors.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.